Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives
- 15 March 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Xenobiotica
- Vol. 40 (5), 357-367
- https://doi.org/10.3109/00498251003663724
Abstract
Baicalin was extensively researched for utility in a number of therapeutic areas owing to its anti-inflammatory, anti-oxidant, anti-bacterial, and anti-cancer properties. A number of preclinical studies, in vitro work, and mechanistic studies were performed to understand the absorption, distribution, metabolism, and excretion profiles of baicalin. The absorption of baicalin involved several complexities: the restriction to two distant sites; the conversion of baicalin to baicalein; the possible role of transporter(s); and enhanced absorption due to breakdown of conjugates by beta-glucuronidase. Limited distribution data suggest that baicalin reached several sites such as the brain, eye lens, thymus, etc. Hepatobiliary recycling also served as a distribution phase for sustained delivery of baicalin. Metabolism data suggest the rapid conversion of baicalin to baicalein, which was extensively subjected to Phase 2 metabolism, conjugates baicalein glucuronide/sulfate have been identified. Limited excretion data suggest involvement of renal and faecal routes--glucuronide and sulfate conjugates were excreted in urine and faeces (via biliary excretion). The published data on baicalin suggest imminent challenges for developing baicalin and/or during co-administration with other agents. These challenges are absorption related (transporter or changes in the microenvironment), metabolism related (CYP2B6 induction and/or CYP2E1 inhibition), and excretion/efflux related (competitive biliary pathway and/or OATP1B1 transport).Keywords
This publication has 51 references indexed in Scilit:
- Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus PatientsAntimicrobial Agents and Chemotherapy, 2009
- Artemisinin–a possible CYP2B6 probe substrate?Biopharmaceutics & Drug Disposition, 2009
- The Role of pH in the Glucuronidation of Raloxifene, Mycophenolic Acid and EzetimibeMolecular Pharmaceutics, 2009
- Hepatic Contribution to a Marked Increase in the Plasma Concentration of Baicalin after Oral Administration of Its Aglycone, Baicalein, in Multidrug Resistance-Associated Protein 2-Deficient RatBiological & Pharmaceutical Bulletin, 2009
- Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylationEuropean Journal of Clinical Pharmacology, 2008
- The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion-transporting Polypeptide 1B1Clinical Pharmacology & Therapeutics, 2007
- Phenotyping of Cytochrome P450 2E1 In Vitro and In VivoCurrent Drug Metabolism, 2007
- Gradient high-performance liquid chromatography for the simultaneous determination of chlorogenic acid and baicalin in plasma and its application in the study of pharmacokinetics in ratsJournal of Pharmaceutical and Biomedical Analysis, 2007
- Enteric Excretion of Baicalein, a Flavone of Scutellariae Radix, via Glucuronidation in Rat: Involvement of Multidrug Resistance-Associated Protein 2Pharmaceutical Research, 2004
- Balicalin, the Predominant Flavone Glucuronide of Scutellariae Radix, is Absorbed from the Rat Gastrointestinal Tract as the Aglycone and Restored to its Original FormJournal of Pharmacy and Pharmacology, 2000